Last reviewed · How we verify
SPARC1104 modified dose regimen II
SPARC1104 is a modified dose regimen of an undisclosed drug, but it is likely a small molecule targeting a specific molecular pathway.
SPARC1104 is a modified dose regimen of an undisclosed drug, but it is likely a small molecule targeting a specific molecular pathway. Used for Undisclosed indication.
At a glance
| Generic name | SPARC1104 modified dose regimen II |
|---|---|
| Sponsor | Sun Pharma Advanced Research Company Limited |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action is unknown, but it is believed to work through a specific molecular target. Further research is needed to fully understand its effects on the body.
Approved indications
- Undisclosed indication
Common side effects
- Unknown
Key clinical trials
- Safety Study of SPARC1104 (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: